泛癌中SMYD3的表达与预后及免疫浸润之间的关系

doi:10.16352/j.issn.1001-6325.2023.01.0068

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (1): 68-75.doi: 10.16352/j.issn.1001-6325.2023.01.0068

泛癌中SMYD3的表达与预后及免疫浸润之间的关系

陈浩然, 司甜, 姜懿珅, 王殿恒, 周雅博, 吕家迪^*

中国医学科学院基础医学研究所北京协和医学院基础学院免疫学系医学分子生物学国家重点实验室,北京 10000)

收稿日期:2022-10-10 修回日期:2022-11-15 出版日期:2023-01-05 发布日期:2022-12-27
通讯作者: ^*lvjiadi666@sina.com
基金资助:
国家自然科学基金(82003145)

Relationships between progrosis, immune infiltration and expression of SMYD3 in pan-cancer

CHEN Haoran, SI Tian, JIANG Yishen, WANG Dianheng, ZHOU Yabo, LYU Jiadi^*

National Key Laboratory of Medical Molecular Biology,Department of Immunology, Institute of Basic Medical Sciences CAMS,School of Basic Medicine PUMC,Beijing 100005,China

Received:2022-10-10 Revised:2022-11-15 Online:2023-01-05 Published:2022-12-27
Contact: ^*lvjiadi666@sina.com

摘要/Abstract

摘要： 目的研究SMYD3表达在泛癌中的预后价值,分析SMYD3对于肿瘤组织免疫浸润的影响。方法从TCGA、GTEx、HPA等数据库收集基因表达矩阵以及蛋白质表达等数据。使用Kaplan-Meier算法评价了SMYD3在不同肿瘤中的预后价值。使用ESTIMATE算法和Timer数据库的信息分析SMYD3与免疫浸润的关系。以小鼠黑色素瘤细胞系B16为例,在细胞水平验证SMYD3对抗原提呈基因表达的影响。结果转录组和蛋白组学数据表明SMYD3在肿瘤组织中表达升高,并且SMYD3的高表达和泛癌的不良预后相关(P<0.05);SMYD3抑制了多种免疫细胞的浸润(P<0.05),敲除Smyd3的B16细胞抗原呈递基因表达水平升高(P<0.05)。结论 Smyd3是一个重要的肿瘤预后相关基因,其通过下调抗原递呈基因的表达,抑制免疫细胞浸润,诱导肿瘤细胞免疫逃逸。

关键词: SMYD3, 泛癌分析, 免疫浸润, 免疫逃逸, MHC-I类分子

Abstract: Objective The study focuses on the prognostic value of SMYD3 in pan cancer, and analyze the influence of SMYD3 on tumor tissue immune infiltration. Methods The gene expression and protein density data were collected from TCGA, GTEx and HPA databases. Kaplan-Meier(KM) algorithm was used to evaluate the impact of SMYD3 on the prognosis of patients with different kinds of tumor. The ESTIMATE algorithm and Timer database were applied to investigate the relationship between SMYD3 and immune microenvironment. And the results were verified in B16 cell line by knockout SMYD3. Results Higher expression of SMYD3 was observed in tumor tissue than normal tissue in both mRNA and protein level. And SMYD3 was thought to be associated with worse outcomes of patients(P<0.05) and less immune cells inflation in tumor tissue(P<0.05). Knockout Smyd3 in B16 cell line increased the expression of antigen present genes(P<0.05). Conclusions Smyd3 is an important gene related to the prognosis of patients and the antigen presentation function of tumor cells. Smyd3 can inhibit the infiltration of immune cell by down-regulation of antigen-present genes, which induces the immune escape.

Key words: SMYD3, pan-cancer, immune infiltration, immune escape, MHC class Ⅰ molecule

中图分类号:

R730.3

陈浩然, 司甜, 姜懿珅, 王殿恒, 周雅博, 吕家迪. 泛癌中SMYD3的表达与预后及免疫浸润之间的关系[J]. 基础医学与临床, 2023, 43(1): 68-75.

CHEN Haoran, SI Tian, JIANG Yishen, WANG Dianheng, ZHOU Yabo, LYU Jiadi. Relationships between progrosis, immune infiltration and expression of SMYD3 in pan-cancer[J]. Basic & Clinical Medicine, 2023, 43(1): 68-75.

参考文献 12

[1]	Van Aller GS, Reynoird N, Barbash O, et al. Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation[J]. Epigenetics, 2012, 7: 340-343.
[2]	Bernard BJ, Nigam N, Burkitt K, et al. SMYD3: a regulator of epigenetic and signaling pathways in cancer[J]. Clin Epigenetics, 2021, 13: 45.
[3]	Fu W, Liu N, Qiao Q, et al. Structural basis for substrate preference of SMYD3, a SET domain-containing protein lysine methyltransferase[J]. J Bio Chem, 2016, 291: 9173-9180.
[4]	Mazur PK, Reynoird N, Khatri P, et al. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer[J]. Nature, 2014, 510: 283-287.
[5]	Zhang H, Zheng Z, Zhang R, et al. SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters[J]. Cell Death Dis, 2021, 12: 731.
[6]	Fenizia C, Bottino C, Corbetta S, et al. SMYD3 promotes the epithelial-mesenchymal transition in breast cancer[J]. Nucleic Acids Res, 2019, 47: 1278-1293.
[7]	Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data[J]. Nat Commun, 2013, 4: 2612.
[8]	Li T, Fan J, Wang B, et al. TIMER: a Web server for comprehensive analysis of tumor-infiltrating immune cells[J]. Cancer Res, 2017, 77: e108-e110.
[9]	Liu D, Schilling B, Liu D, et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 block-ade in patients with metastatic melanoma[J]. Nat Med, 2019, 25: 1916-1927.
[10]	Yamamoto K, Venida A, Yano J, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I[J]. Nature, 2020, 581: 100-105.
[11]	Dhatchinamoorthy K, Colbert J D, Rock K L. Cancer immune evasion through loss of MHC class Ⅰ antigen presentation[J]. Front Immunol, 2021, 12: 636568.
[12]	Sarris ME, Moulos P, Haroniti A, et al. Smyd3 is a transcriptional potentiator of multiple cancer-promoting genes and required for liver and colon cancer development[J]. Cancer Cell, 2016, 29: 354-366.

泛癌中SMYD3的表达与预后及免疫浸润之间的关系

Relationships between progrosis, immune infiltration and expression of SMYD3 in pan-cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 12

相关文章 4

编辑推荐

Metrics

本文评价

[1]	陈忠婕, 黄嘉如, 胡清, 赵珍琴, 陈俏俏, 孙浚源, 贾静. 免疫检查点CD276蛋白参与肿瘤发生发展作用机制的研究进展[J]. 基础医学与临床, 2023, 43(7): 1143-1147.
[2]	李昱阳, 李钊璇, 罗云萍, 陈翀. 小鼠乳腺癌干细胞免疫相关分子表达和免疫浸润的分析[J]. 基础医学与临床, 2022, 42(6): 876-882.
[3]	苏路瑛, 黄容, 邹定峰, 许富, 李凯, 卢艳, 缪时英, 王琳芳, 宋伟. 多组学分析发现LAMC2是调节泛癌微环境的关键因子[J]. 基础医学与临床, 2022, 42(4): 545-552.
[4]	陈佳骏张中卒. 外排体是肿瘤优势生存的开拓者[J]. 基础医学与临床, 2017, 37(8): 1190-1194.